TD Cowen analyst Joshua Jennings lowered the firm’s price target on Tandem Diabetes to $34 from $52 and keeps an Outperform rating on the shares. The firm said the 2Q report included a dramatic reduction in 2023 revenue guidance and the firm believes a reset like this was arguably needed and they are optimistic that it positions the company to start beating numbers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNDM: